Skip to content
Calculator
Evidence: HighPeptideFDA ApprovedPTHrP(1-34) analogFDA-approved · TymlosOsteoporosis

Abaloparatide

A synthetic version of the first 34 amino acids of PTHrP, injected daily to build bone in osteoporosis

Abaloparatide is a synthetic analog of the first 34 amino acids of parathyroid hormone-related peptide, injected once a day. Approved as Tymlos in 2017 for osteoporosis at high fracture risk, it reduced new spine fractures against placebo in the ACTIVE trial.

Manufacturer's recommended dosing (FDA label): 80 µg, Once daily, at about the same time, Subcutaneous, periumbilical abdomen Details ↓

Overview

What is it?

Parathyroid hormone and its relative, parathyroid hormone-related peptide (PTHrP), act on the same receptor, PTH1R. Teriparatide was the first drug to use a brief daily pulse there to build bone. Abaloparatide is the second: an analog of the first 34 amino acids of PTHrP, described in its phase 3 report as a selective activator of the type 1 PTH receptor.

In the ACTIVE trial, 2,463 postmenopausal women took abaloparatide, placebo or teriparatide for 18 months. Spine and non-spine fractures were less frequent on abaloparatide than on placebo, and high blood calcium was less common than on teriparatide, 3.4% against 6.4%. After two further years on alendronate, 0.9% of women who had started on abaloparatide had a new spine fracture, against 5.6% who had started on placebo.

The benefit held among the women most at risk. In the 2,026 ACTIVE participants who met guideline definitions of high fracture risk, new spine fractures occurred in 0.72% on abaloparatide against 4.77% on placebo. In men, the ATOM trial measured bone density rather than fractures: spine density rose 8.48% against 1.17% on placebo over a year, and that is why the men's indication is to increase bone density. A Japanese dose-finding study showed the effect scales with dose, 80 µg outperforming 40 µg.

Claims data compare it with teriparatide in practice. Among more than 11,000 matched patients on each, non-vertebral fractures and cardiovascular events were similar. Osteosarcoma is the standing concern, because abaloparatide caused it in rats at 4 to 28 times the human exposure (label); in 44,728 patients prescribed teriparatide or abaloparatide, primary bone cancer was no more common than in matched controls. Not every hoped-for use worked: in a small trial after pelvic fracture, abaloparatide did not speed healing.

Tymlos is approved in the US for postmenopausal women and men with osteoporosis at high fracture risk. The dose is 80 µg once a day under the skin of the abdomen, and use beyond two years in a lifetime is not recommended. First doses are taken sitting or lying down, as blood pressure can drop on standing; the label also warns about allergic reactions, osteosarcoma risk and high blood calcium.

80 µg
Once daily, under the skin
Tymlos label
0.72% vs 4.77%
New spine fractures, highest-risk women
Abaloparatide against placebo · PMID 39999474
2 years
Lifetime limit recommended
Tymlos label
Science

Mechanism of Action

Abaloparatide is an analog of PTHrP(1-34) that activates the PTH1 receptor; given once a day as a brief pulse, it stimulates bone-forming cells (label).

🎯

PTH1 receptor

Acts as an agonist at PTH1R and switches on cAMP signalling in target cells (label).

🦴

Bone formation

Once-daily dosing stimulates osteoblasts on trabecular and cortical bone; the formation marker PINP rose 140.7% on 80 µg in the Japanese study.

⏱️

A short pulse

Levels peak about 30 minutes after injection and the half-life is about 1 hour, so exposure is brief each day (label).

Evidence

Published Research

The studies behind abaloparatide, read from their PubMed abstracts.

Human2016

ACTIVE: abaloparatide against placebo, 2,463 women

Postmenopausal women received abaloparatide 80 µg daily, placebo or teriparatide for 18 months. Spine and non-spine fractures were less frequent than on placebo and bone density rose more (P < .001); high blood calcium occurred in 3.4% against 6.4% on teriparatide.

PMID: 27533157
Human2018

ACTIVExtend: alendronate after abaloparatide, 1,139 women

Women who finished ACTIVE took alendronate for up to 24 months. Over 43 months, 0.9% who had started on abaloparatide had a new spine fracture against 5.6% who had started on placebo, an 84% relative risk reduction.

PMID: 29800372
Human2022

ATOM: men with osteoporosis, 228 randomized

Men aged 40 to 85 took abaloparatide 80 µg or placebo daily for 12 months. Spine bone density rose 8.48% against 1.17%, total hip 2.14% against 0.01% (both p < 0.0001); injection-site reactions, dizziness and headache were among the commonest side effects.

PMID: 36190391
Human2022

ACTIVE-J: Japanese women and men, 78 weeks

Abaloparatide 80 µg daily for 78 weeks raised spine bone density 12.5% more than placebo, and total hip and femoral neck density 4.3% more each.

PMID: 35977548
Human2023

A skin patch against the injection, 511 women

Women used an experimental abaloparatide skin patch or the injection daily for 12 months. Spine bone density rose 7.14% with the patch against 10.86% with the injection, missing the trial's 2.0-point non-inferiority margin; application-site reactions affected 94.4% against 70.5%.

PMID: 37417725
Human2025

Insurance claims: abaloparatide against teriparatide

Among propensity-matched women aged 50 and over, hip fractures over 18 months occurred in 1.1% on abaloparatide against 1.4% on teriparatide (hazard ratio 0.83), and non-spine fractures in 4.4% against 5.0%. Observational, not randomized.

PMID: 39551187
Human2025

Women at the highest fracture risk

In the 2,026 ACTIVE participants who met guideline criteria for high fracture risk, new spine fractures occurred in 0.72% on abaloparatide, 0.99% on teriparatide and 4.77% on placebo; major osteoporotic fractures in 1.6%, 3.0% and 6.8%.

PMID: 39999474
Human2023

Japanese dose-finding, 48 weeks

In postmenopausal Japanese women at high fracture risk, spine bone density rose 6.6% on 40 µg and 11.5% on 80 µg more than placebo; adverse events were more common on abaloparatide but mild to moderate.

PMID: 37505256
Human2022

Claims data: heart safety against teriparatide

Among 11,616 propensity-matched patients per group, non-vertebral fractures over 19 months were similar to teriparatide (hazard ratio 0.89) and major cardiovascular events occurred at similar rates.

PMID: 35524068
Human2023

Bone cancer in 44,728 patients

In 44,728 patients over 50 prescribed teriparatide or abaloparatide, primary bone cancer occurred in 0.02% against 0.05% of matched controls who had no known risk factors (risk ratio 0.47).

PMID: 36913523
Human2026

Pelvic fracture healing: no benefit

In 48 adults aged 50 and older randomized within four weeks of a pelvic fracture, CT healing at three months was no better than placebo (39% against 64% of patients healed, not significant), and pain and mobility did not differ.

PMID: 42618812
Dosing

Dosing Data

Tymlos is 80 µg injected under the skin of the abdomen once a day, with calcium and vitamin D if the diet falls short.

Prescription only. Use for more than two years in a lifetime is not recommended; take the first doses sitting or lying down.
ProtocolDoseFrequencyDurationRoute
Label: osteoporosis at high fracture risk (postmenopausal women; men, to increase bone density) Approved labelTYMLOS (abaloparatide) injection Prescribing Information, sections 1, 2, 5, 12 and 14 (DailyMed version 19, effective August 11, 2026)80 µgOnce daily, at about the same timeUp to 2 years in a lifetimeSubcutaneous, periumbilical abdomen

Educational information, not medical advice. Each dose above is tagged with its source: an approved label, a published human study, animal data, or amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.

Fixed dose
Each Tymlos pen delivers 30 fixed doses of 80 µg; there is nothing to calculate.
Open Calculator →
For Buyers

What a Buyer Needs to Know

What is sold, how it is mixed, stored and taken, and what is known about its safety, quality and legal status. Each part names its source. Where we have none, it says unknown.

What is sold

The approved product, as its label describes it:

  • Tymlos (abaloparatide injection): Injection: 3120 mcg/1.56 ml (2000 mcg/ml) of abaloparatide in clear, colorless solution in a single-patient-use prefilled pen. The prefilled pen delivers 30 daily doses of 80 mcg abaloparatide in 40 mcl. Forms the label lists: single-patient-use prefilled pens.

Source: Tymlos (abaloparatide injection) label, section 3 (DailyMed version 19, effective August 11, 2026).

Mixing a vial: a worked example

Nothing to mix: the label gives Tymlos (abaloparatide injection) as single-patient-use prefilled pens, ready to use.

Source: Tymlos (abaloparatide injection) label, sections 2, 3 and 16 (DailyMed version 19, effective August 11, 2026).

Storage before and after mixing

Before mixing or first use: “Storage and Handling Before first use, store TYMLOS under refrigeration between 2°C to 8°C (36°F to 46°F).” “Do not freeze or subject to heat.”

After mixing or first use: “After first use, store for up to 30 days at 20°C to 25°C (68°F to 77°F).”

Source: Tymlos (abaloparatide injection) label, sections 16 and 2 (DailyMed version 19, effective August 11, 2026).

How it is taken

As the approved label gives it: Subcutaneous, periumbilical abdomen (Once daily, at about the same time; Label: osteoporosis at high fracture risk (postmenopausal women; men, to increase bone density)).

Source: Manufacturer's recommended dosing (FDA label): the route and frequency of each row in Dosing Data below.

What to expect, and when

How long it stays in the body: a half-life of about 1 hour after subcutaneous injection. After about five half-lives almost none is left.

How long the doses were given: Label: osteoporosis at high fracture risk (postmenopausal women; men, to increase bone density): Up to 2 years in a lifetime.

When effects appear: unknown; no source on this page gives a time to effect for Abaloparatide. Results reported in the studies are under Published Research.

Source: half-life: Tymlos prescribing information, section 12.3 (DailyMed set 712143d9-e21e-4013-bb3b-3426a21060a8, effective August 11, 2026; read October 2, 2026); Manufacturer's recommended dosing (FDA label), the duration of each row in Dosing Data below.

Side effects, and when to stop or get help

From the Side Effects section: Injection-site reactions, dizziness and headache were among the most common in men (ATOM); High blood calcium: 3.4% against 6.4% on teriparatide (ACTIVE); Application-site reactions in most users of the experimental patch. Full list and cautions ↓

When to stop or get help: unknown; the label's warnings summary we read gives no rule for stopping Abaloparatide. Treat a severe or unexpected reaction as a reason to stop and see a doctor.

Source: the Side Effects section below (“From the trials above”).

Interactions

Unknown: a PubMed search for human interaction studies of Abaloparatide (reviewed 2026-10-06) found none. Unknown is not the same as safe to combine.

Every peptide's record, with its source: the interaction matrix.

Checking what you bought

Unknown: no published independent test of Abaloparatide products is in our lab-results database yet, so how products sold under this name measure up is not known.

To read a certificate of analysis, paste it into the COA decoder; it checks the measured mass against Abaloparatide's expected mass, 3,961.0 Da, from this entry's molecular data. Trust & Verification explains what independent testing can and cannot show.

Legal status

US: FDA Approved (Approved in the US as Tymlos (abaloparatide injection), NDA 208743, first approved April 28, 2017). Sport: Not on the 2026 List.

Country by country ↓ · Regulatory tracker

Source: this entry's approval status and the WADA Prohibited List, as in Legal Status below.

Safety

Side Effects & Contraindications

Reported Side Effects

From the trials above.

● Injection-site reactions, dizziness and headache were among the most common in men (ATOM)
● High blood calcium: 3.4% against 6.4% on teriparatide (ACTIVE)
● Application-site reactions in most users of the experimental patch

Contraindications & Cautions

From the Tymlos label (DailyMed, effective August 11, 2026).

● Raised risk of osteosarcoma, including open growth plates, Paget's disease, bone metastases or past radiation to the skeleton
● Pre-existing high blood calcium or a disorder that causes it, such as primary hyperparathyroidism
● A previous severe allergic reaction to the drug
● Tested athletes — see the Sport (WADA) row below
Questions

Frequently Asked Questions

?What is abaloparatide?

A synthetic analog of the first 34 amino acids of parathyroid hormone-related peptide, injected once a day to build bone. It is sold in the US as Tymlos.

?How is it different from teriparatide?

Both give a daily pulse at the same receptor; teriparatide copies parathyroid hormone, abaloparatide PTHrP. High blood calcium was less common on abaloparatide in ACTIVE, 3.4% against 6.4%.

?What dose is used?

The labelled dose is 80 micrograms under the skin of the abdomen once a day.

?Does it prevent fractures?

In ACTIVE, spine and non-spine fractures were less frequent than on placebo over 18 months; with two years of alendronate afterwards, new spine fractures occurred in 0.9% against 5.6%.

Bibliography

References

  1. [fda] FDA. Drugs@FDA (openFDA): TYMLOS (abaloparatide) injection, NDA 208743, original approval April 28, 2017, prescription. Read October 2, 2026.
  2. [fda] FDA. Tymlos (abaloparatide) injection US prescribing information (DailyMed set 712143d9-e21e-4013-bb3b-3426a21060a8, version 19, effective August 11, 2026). Read October 2, 2026.
  3. [clinical-trial] Miller PD, et al. "Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial." JAMA, 2016;316(7):722-33. PMID: 27533157.
  4. [clinical-trial] Bone HG, et al. "ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis." J Clin Endocrinol Metab, 2018;103(8):2949-2957. PMID: 29800372.
  5. [clinical-trial] Czerwinski E, et al. "The Efficacy and Safety of Abaloparatide-SC in Men With Osteoporosis: A Randomized Clinical Trial." J Bone Miner Res, 2022;37(12):2435-2442. PMID: 36190391.
  6. [clinical-trial] Matsumoto T, et al. "Abaloparatide Increases Lumbar Spine and Hip BMD in Japanese Patients With Osteoporosis: The Phase 3 ACTIVE-J Study." J Clin Endocrinol Metab, 2022;107(10):e4222-e4231. PMID: 35977548.
  7. [clinical-trial] Lewiecki EM, et al. "Efficacy and Safety of Transdermal Abaloparatide in Postmenopausal Women with Osteoporosis: A Randomized Study." J Bone Miner Res, 2023;38(10):1404-1414. PMID: 37417725.
  8. [pubmed] Tabatabai L, et al. "Comparative Effectiveness of Abaloparatide and Teriparatide in Women 50 Years of Age and Older: Update of a Real-World Retrospective Analysis." Endocr Pract, 2025;31(2):159-168. PMID: 39551187.
  9. [pubmed] DeSapri KT, et al. "Effect of abaloparatide on fracture incidence and bone mineral density in postmenopausal women with osteoporosis at highest risk for fracture." Menopause, 2025;32(5):388-395. PMID: 39999474.
  10. [pubmed] Matsumoto T, et al. "Abaloparatide dose-dependently increases bone mineral density in postmenopausal women with osteoporosis: a phase 2 study." J Bone Miner Metab, 2023;41(6):807-816. PMID: 37505256.
  11. [pubmed] Cosman F, et al. "Comparative effectiveness and cardiovascular safety of abaloparatide and teriparatide in postmenopausal women new to anabolic therapy: A US administrative claims database study." Osteoporos Int, 2022;33(8):1703-1714. PMID: 35524068.
  12. [pubmed] McDonald CL, et al. "Treatment of Osteoporosis With Anabolic Agents and the Risk of Primary Bone Cancers: A Study of 44,728 Patients Treated With Teriparatide and Abaloparatide." J Am Acad Orthop Surg, 2023;31(10):520-528. PMID: 36913523.
  13. [pubmed] Nieves JW, et al. "Abaloparatide and pelvic fracture healing: a phase 2 randomized placebo-controlled trial." Osteoporos Int, 2026. PMID: 42618812.

Sources & Citations

Studies were read from their PubMed abstracts; the Tymlos label (DailyMed version 19, effective August 11, 2026) was read October 6, 2026.

Medical Disclaimer: This content is for educational and informational purposes only. It is not medical advice, and nothing here is an instruction to obtain or use any compound. Talk to a licensed clinician about your own situation.

Last reviewed: 2026-10-02